Week 334 Review - A good end to the year thanks to Optibiotix

The final week of 2021 gave a little bit of seasonal cheer with a 3p rise in OPTI:Optibiotix resulting in a narrowing of the deficit between cost and value by £5,002. Unfortunately that means the rest of my portfolio was down by £100, but it's nice to see OPTI sneaking back upwards again on news of yet more deals and promise of some big ones in the new year. The deficit is now £50,303 and the total portfolio value is £105,214.

Looking back 12 months, the total value then was £120,024 which is £15k more than the current value, and I've added £11,555 during the year, so the total value is down by £26.5k in real terms. However last year there was a £12.7k rise in the last week of the year as OPTI:Optibiotix was soaring, but that turned out to be very short lived. I'll compare my long term performance stats against each account when I cover the numbers.

No big fallers this week, although a 2% drop in DDDD:4D Pharma was expensive and that is more than 50% down on my purchase price now.

BLU:Blue Star Capital climbed 5% and seems to have some momentum. It's only 45% down now. Will it ever get into profit?

OPTI:Optibiotix also climbed 5% after a torrid few months. If we can just get established back in the 50's then that will help remove a big chunk of my losses until we get the longer term re-rate.

Share of the Week is JLP:Jubilee Metals which climbed 7%. I'm a bit nervous about the short term prospects as they are talking about a new global expansion plan, and that could result in a placing - particularly as institutions are probably pushing for one if they want to get in and are not prepared to buy on the open market. One of the problems with the management board having practically no shares is the temptation for continued dilution. I need a war chest as I think it would be worth buying more if there's a big drop following a placing announcement.

A good bounce, but we're still below the value 3 weeks ago,

Bang on the trend line so at least it's not getting steeper

Here's the ISA and shares portfolio after week 22 of year 7.

			Weekly Change
Cash	£37.05		+£0
Portfolio cost	£72,195.21		+£0
Portfolio sell value (bid price-commission)	£49,197.95	(-31.9%)	+£2,583.71
Potential profits	£2,315.29		+£60
Yr 7 Dividends	£22.16		+£0
Yr 7 Profit from sales	£3,664.29		+£0
Yr 7 projected avg monthly profit	£723.16	(19.6%)	-£34.44
Total Dividends	£1,365.31		+£0
Total Profit from sales	£27,788.23		+£0
Average monthly cash profit	£374.39	(10.2%)	-£1.13
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	65%		+0%

JLP:Jubilee Metals increased potential profits by £60, value up nicely thanks to OPTI:Optibiotix and long term performance still above target at 10.2% compared to 9.8% this time last year. So although the portfolio value itself is down 31.9% rather than only 8% last year, performance on selling shares and dividends is slightly better.

Very similar to combined chart

Still below the trend line so still dragging it steeper.

The SIPP looks like this after week 318 overall and week 6 of year 7.

/>

			Weekly Change
Cash	£229.74		+£40.31
Portfolio cost	£80,422.42		+£30.00
Portfolio sell value (bid price - commission)	£54,566.20	(-32.2%)	+£2,439.07
Potential profits	£47.60		+£32.31
Yr 7 Dividends	£51.51		+£10.31
Yr 7 Interest	£0		+£0
Yr 7 Profit from sales	£381.04		+£0
Yr 7 projected avg monthly profit	£300.25	(7.3%)	-£51.12
Total Dividends	£3,255.90		+£10.31
Total Interest	£0.20		+£0
Total Profit from sales	£24,105.67		+£0
Average monthly cash profit	£361.42	(8.8%)	-£1.00
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	54%		+0%

Cash increased following a £30 tax rebate in my AJ Bell account and a £10.31 dividend from WHR:Warehouse REIT. There was also a £30 tax rebate in my Hargreaves Lansdown account, and that automatically invested in Blackrock World Gold fund. That's the last of these, so I'll sell at some point soon so I'll only have the one gold fund in my other account. Potential profits are mainly up thanks to PAF:Pan African Resources. The only other thing in profit is iShares Physical Gold, but that's only contributing £1. Great rise in value as with the ISA, and long term performance still ok at 8.8% compared with 8.6% this time last year. The account was only 3.7% in deficit last year compared to 32.2% this year.

Same shape as the ISA

Above the trend line so let's hope we can start pulling it upwards.

The trading account looks like this after week 284 overall and week 24 of year 6.

			Weekly Change
Cash	£259.74		+£0
Portfolio cost	£2,374.14		+£0
Portfolio sell value (bid price - commission)	£923.93	(-61.1%)	-£20.30
Potential profits	£0.00		+£0
Year 6 Dividends	£0.00		+£0
Year 6 Profit	£0.00		+£0
Yr 6 projected avg monthly profit	£0.00	(0%)	+£0
Dividends	£60.10		+£0
Profit from sales	£937.88		+£0
Average monthly cash profit	£15.23	(7.7%)	-£0.05
(Sold stocks profit + Dividends - Fees / Months)

The drop in DDDD:4D Pharma hit this account yet again. I desperately need some news from them. Long term performance is at 7.7% compared to 8.6% this time last year which was just after selling a load for profit and re-investing in DDDD. A whole year since that terrible mistake. The account was 16.6% down compared to 61.1% down now.

Not the lowest ever but not far off.

Fractionally above the trend line but following it down.

2021 has been a good year for improving long term performance, with the main accounts both making more from realised profits and dividends than at the start of the year. However it has been a desperate year for portfolio value, with nearly everything I own making a loss, including all bar 1 of my magic formula shares.

My biggest holdings are OPTI:Optibiotix and DDDD:4D Pharma, which have both been hammered this year. My magic formula shares are mostly split between share trading companies which crashed when one of their peers gave a profit warning, and gold miners that are being hammered despite gold being above $1,800.

Let's hope 2022 is kinder to my portfolio holding and we can get back towards break-even.